Erbitux Add-On Falls Short in Esophageal Ca (CME/CE)

SAN FRANCISCO (MedPage Today) -- The addition of cetuximab (Erbitux) to definitive chemoradiation failed to improve survival in an unselected population with esophageal cancer, a randomized trial showed. via MedPageToday.com - medical news plus CME for physicians Read More Here..

For a Free Step By Step Guide for Dating Dos and Don'ts check http://end2endwebs.com

Lake forest health and fitness http://healthandfitness1blog.blogspot.com/2013/01/erbitux-add-on-falls-short-in.html